Cardiome (Canada)

Recent papers from Cardiome (Canada)

1. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationJournal of the American College of Cardiology · 2004
2. A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial FibrillationJournal of the American College of Cardiology · 2011
3. Impact of Oxypurinol in Patients With Symptomatic Heart FailureJournal of the American College of Cardiology · 2008
4. Lessons Learned and Recommendations from a SCOPE Spinal Cord Injury Neurorestorative Clinical Trials UpdateNeurotrauma Reports · 2025
5. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonistsObesity Reviews · 2023
6. Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI StudyCJC Open · 2022
7. ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraineJournal of Managed Care & Specialty Pharmacy · 2020
8. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia–Pacific Region: A Phase 3 Randomized Controlled TrialJournal of Cardiovascular Pharmacology · 2016
9. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trialBMC Cardiovascular Disorders · 2016
10. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conferenceEP Europace · 2015
11. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillationCardiovascular Research · 2013
12. Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac TissuesJournal of Cardiovascular Pharmacology · 2012
13. Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium ChannelCirculation Arrhythmia and Electrophysiology · 2012
14. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trialEP Europace · 2012
15. Synthesis of 2-amino-imidazoles, purines, and benzoxazolamines through DIB oxidationRSC Advances · 2012
16. A Randomized, Placebo-Controlled Study of Vernakalant (Oral) for the Prevention of Atrial Fibrillation Recurrence After CardioversionCirculation Arrhythmia and Electrophysiology · 2011
17. Comparison of the In Vivo Hemodynamic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in a Rat Hindlimb Perfusion ModelJournal of Cardiovascular Pharmacology · 2011
18. Pharmacokinetics of Novel Atrial‐Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other FactorsThe Journal of Clinical Pharmacology · 2008
19. Synthesis and Biological Studies of Novel 2-Aminoalkylethers as Potential Antiarrhythmic Agents for the Conversion of Atrial FibrillationJournal of Medicinal Chemistry · 2007
20. The Role of Late INa and Antiarrhythmic Drugs in EAD Formation and Termination in Purkinje FibersJournal of Cardiovascular Electrophysiology · 2006